More than 10 percent of individuals in an unselected population carried recurrent syndrome-associated CNVs or rare autosomal CNVs with potential ties to cognitive ability.
The company has also received approvals for various molecular diagnostics in the US and Canada in recent months.
The investigators used the technique to identify two novel secretome targets and then confirmed them to be elevated in the blood of women with cancer.
In a 6,000-patient study, Eskenazi Health will assess whether PGx testing improves outcomes and saves money in a community that doesn't usually have access to genomic advances.
The company said the proceeds will be used to refine its core technology and improve manufacturing.
David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.
In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.
Adam Rutherford discusses genetic genealogy at the Guardian.
Portions of the US 21st Century Cures Act are raising some safety concerns.